Stocks / NASDAQ / Ventyx Biosciences Inc.

Ventyx Biosciences Inc.

Our Opinion

Ventyx Biosciences Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“VTX2735 has demonstrated NLRP3 inhibition in cellular assays, in vivo pharmacodynamic activity in an animal model, and high oral bioavailability in multiple preclinical species. We received IND clearance in September 2021 for VTX2735 and plan to initiate a Phase 1 clinical trial in healthy volunteers in the fourth quarter of 2021.” (Page 2) Read the full document

Company Description

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company’s lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn’s disease, and lupus. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Company Website: